Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 1, 2011, Pages 1-15

  Ait Oudhia, Sihem ^a,c   Vermeulen, An ^b   Krzyzanski, Wojciech ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

chemotherapy induced anemia; recombinant human erythropoietin; simplistic pharmacokinetic model; time variant pharmacokinetics

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; MALE; MATHEMATICAL MODEL; POPULATION MODEL; TIMED DRUG RELEASE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NONLINEAR DYNAMICS; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 78650324702     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.733     Document Type: Article

References (46)

1. Groopman JE, Itri LM,. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
2. Schwartz RN,. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 2007; 64: S5-S13; quiz S28-S30.
3. Canaparo R, Casale F, Muntoni E, et al,. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 2000; 50: 146-153.
4. Ludwig H, Fritz E,. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 1998; 25: 35-38.
5. Ludwig H, Fritz E,. Anemia in cancer patients. Semin Oncol 1998; 25: 2-6.
6. Egrie JC, Browne JK,. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 (Suppl 1): 3-10.
7. Morreale A, Plowman B, DeLattre M, Boggie D, Schaefer M,. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004; 20: 381-395.
8. Mulcahy L,. The erythropoietin receptor. Semin Oncol 2001; 28: 19-23.
9. Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA,. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 2001; 29: 425-431.
10. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y,. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 1997; 283: 520-527.
11. Veng-Pedersen P, Chapel S, Al-Huniti NH, et al., Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 2004; 25: 149-156.
12. Agoram B, Aoki K, Doshi S, et al,. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci 2009; 98: 2198-2211.
13. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW,. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21: 366-373.
14. Cheung W, Minton N, Gunawardena K,. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57: 411-418.
15. Gabrilove JL,. Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes. Semin Hematol 2001; 38: 1-7.
16. Abels RI,. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992; 19: 29-35.
17. Littlewood TJ,. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001; 28: 49-53.
18. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B,. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
19. Rizzo JD, Lichtin AE, Woolf SH, et al,. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303-2320.
20. Witzig TE, Silberstein PT, Loprinzi CL, et al,. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005; 23: 2606-2617.
21. Woo S, Krzyzanski W, Jusko WJ,. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol 2008; 62: 123-133.
22. Reddy PK, Williams D, Wilhelm FE,. An open-label pilot study to evaluate a flexible dosing regimen of epoetin alfa for the treatment of chemotherapy-induced anemia: 60,000 units weekly followed by 60,000 units every 2 weeks. Support Cancer Ther 2006; 4: 56-62.
23. Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L,. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 2004; 9: 90-96.
24. Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK,. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 2005; 26: 295-306.
25. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ,. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004; 44: 991-1002.
26. Olsson-Gisleskog P, Jacqmin P, Perez-Ruixo JJ,. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinet 2007; 46: 159-173.
27. Agoram B, Heatherington AC, Gastonguay MR,. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 2006; 8: E552-E563.
28. Beal SL, Boeckmann AJ,. NONMEM Users Guides (1989-2006). Icon Development Solutions: Ellicott City, 2006.
29. Ramakrishnan R, Cheung WK, Farrell F, Joffee L, Jusko WJ,. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 2003; 306: 324-331.
30. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS,. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995; 84: 760-767.
31. McLennan DN, Porter CJ, Edwards GA, Martin SW, Heatherington AC, Charman SA,. Lymphatic absorption is the primary contributor to the systemic availability of epoetin alfa following subcutaneous administration to sheep. J Pharmacol Exp Ther 2005; 313: 345-351.
32. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, Lowe LS,. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 1999; 20: 217-223.
33. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-532.
34. McLennan DN, Porter CJ, Edwards GA, Brumm M, Martin SW, Charman SA,. Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. Pharm Res 2003; 20: 1156-1162.
35. Agoram B, Sutjandra L, Sullivan JT,. Population pharmacokinetics of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol 2007; 63: 41-52.
36. Porter CJ, Charman SA,. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000; 89: 297-310.
37. Piroso E, Erslev AJ, Flaharty KK, Caro J,. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol 1991; 36: 105-110.
38. Piroso E, Erslev AJ, Caro J,. Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hematol 1989; 32: 248-254.
39. Knox RJ, Friedlos F, Lydall DA, Roberts JJ,. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986; 46: 1972-1979.
40. Krzyzanski W, Jusko WJ,. Multiple-pool cell lifespan model of hematologic effects of anticancer agents. J Pharmacokinet Pharmacodyn 2002; 29: 311-337.
41. Weiss G, Goodnough LT,. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
42. Wintrobe MM., Wintrobe Clinical Hematology. Lippincott Williams & Wilkins: Philadelphia, 2003.
43. Henke M, Laszig R, Rube C, et al,. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260.
44. Leyland-Jones B,. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459-460. (Pubitemid 37009952)
45. Glaspy J, Henry D, Patel R, et al,. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005; 41: 1140-1149.
46. Hartley C, Elliott S, Begley CG, et al,. Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha. Br J Haematol 2003; 122: 623-636.